A Competitive Inhibitor of Hepatic Fructokinase: Potency In Vitro Versus Exposure In Vivo
A research team is characterizing Z-14, a small molecule that inhibits hepatic fructokinase (KHK-C), in cell-free assays at 25 °C and pH 7.4. Without Z-14 the enzyme has Km = 2.0 mM for fructose and Vmax = 100 µmol/min per mg of purified protein. With 10 µM Z-14, Vmax is 98 µmol/min per mg and Km is 6.0 mM; each value is the mean of four replicates with overlapping standard deviations. Equilibrium dialysis shows that Z-14 binds the free enzyme with a dissociation constant of 5 µM and does not bind the enzyme–fructose binary complex. In fasting human hepatocytes, cytosolic fructose is estimated at 0.4 mM. In mice, Z-14 is 92% bound to plasma albumin, and a pilot pharmacokinetic study reports total plasma concentrations of 30 µM after an oral dose. The team proposes testing Z-14 in hereditary fructose intolerance, a disorder in which fructose-1-phosphate accumulates and damages hepatocytes.
1. Classify the inhibition and derive Ki. Explain how the dialysis result constrains the mechanism, and note any weak point in the kinetic evidence.
Read the worked answer
Vmax is unchanged (98 versus 100, within replicate error) while Km rises from 2.0 to 6.0 mM, a factor of 3. An unchanged Vmax with an increased apparent Km is the signature of competitive inhibition. The dialysis result fits: Z-14 binds only the free enzyme, so substrate and inhibitor compete for mutually exclusive enzyme forms. For competitive inhibition, alpha = 1 + [I]/Ki, where alpha is the Km shift: 3 = 1 + 10 µM/Ki, giving Ki = 5 µM, which matches the dialysis value. That agreement is a consistency check, not independent proof, because both measurements reflect the same binding equilibrium. The 2% Vmax drop should not be over-read; a noncompetitive inhibitor would have lowered Vmax proportionally without changing Km. One weakness: the Km shift is only interpretable because the substrate range spanned Km. If all substrate concentrations had been far below Km, Vmax could not have been assessed at all.
2. Using the kinetic constants, predict fractional inhibition at the fasting cytosolic fructose concentration and at a postprandial concentration of 6 mM. What does this imply for dosing around meals?
Read the worked answer
Use v = Vmax[S]/(Km + [S]). Without Z-14 at 0.4 mM: 100 × 0.4/(2.0 + 0.4) = 16.7 µmol/min/mg. With 10 µM Z-14: 98 × 0.4/(6.0 + 0.4) = 6.1, a 63% decrease. This is the counterintuitive point about competitive inhibitors: they can be outcompeted by substrate, but at 0.4 mM the substrate is one-fifth of Km, so the enzyme is mostly unliganded and there is little substrate present to compete. At 6 mM fructose, velocity falls from 75 to 49, a 35% decrease, and at saturating fructose inhibition approaches zero. The therapeutic implication is conditional. At fasting concentrations the compound is potent, but a fructose load that drives portal fructose into the millimolar range partially overcomes it exactly when KHK flux is highest. A meal-timed dose would need to cover the postprandial transient, so Ki alone is not the right design parameter; fractional inhibition integrated over the fructose excursion is.
3. Given the mouse pharmacokinetics, assess whether the reported exposure supports target engagement in human liver. What measurements would you require next?
Read the worked answer
Total 30 µM with 92% albumin binding leaves about 2.4 µM free, below Ki = 5 µM. At that free concentration alpha = 1 + 2.4/5 = 1.48. At 0.4 mM fructose, velocity would fall from 16.7 to 100 × 0.4/(2.96 + 0.4) ≈ 11.9, only about 29% inhibition, and less at postprandial fructose. Two further cautions apply. First, plasma free concentration is not hepatocyte free concentration: uptake transporters, intracellular binding, and hepatic metabolism can make liver exposure higher or lower than plasma predicts. Second, a single post-dose plasma value is not the relevant exposure metric; trough concentration and the free-drug area under the curve matter. The data therefore support in vitro target engagement but not in vivo. Next steps: measure free Z-14 in hepatocytes or liver tissue, run dose–response in primary hepatocytes at 0.4 and 6 mM fructose, and establish the free-fraction-corrected exposure needed for at least 80% KHK inhibition.